Klotho Neurosciences (KLTO)announced that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. platform technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLTO:
- Klotho Neurosciences seeking to expand into adjacent technologies
- Klotho Neurosciences Partners with AAVnerGene for Gene Therapy
- Klotho Neurosciences partners with AAVnerGene to make gene therapy assets
- Klotho Neurosciences Regains Nasdaq Compliance
- Klotho Neurosciences regains compliance with Nasdaq